Empowered Patient Podcast

Lisbeth Votruba, Chief Clinical Officer at AvaSure, reflects on the challenges for nurses and hospitals in these times of nursing shortages, burnout, and expedited retirements. The AvaSure solutions provide virtual nursing, safety monitoring, and expert virtual nursing to monitor critically ill and high-acuity patients. Experienced nurses and those trained as virtual nurses embrace this solution as a way to care for patients while supporting the efficient use of hospital resources for bedside care.

Lisbeth explains, "The first model that I'll talk about is the Telesitter® solution, which supports nurses indirectly. This involves using mobile devices or sometimes fixed cameras with really amazing audio in patient rooms. We are using that to keep patients safe, prevent falls, prevent elopement. This also was used to protect nurses from COVID because patients were ripping off their oxygen masks because they were confused and reminding them to put their masks back on again."

"Prior to this revolution in virtual patient monitoring in the hospital setting, the only thing that hospitals could think to do was assign one-to-one what they called "sitters" to confused or at-risk patients. So 5% of the hospital census would have a staff member, not a nurse, a nursing assistant sitting 24/7, watching them and trying to keep them safe physically. The Telesitter® solution allows one remote, trained staff member to monitor 12 to 16 patients, interacting with them, talking to them, and sometimes needing to use alarms to keep them safe. That frees up that bedside staff to be back out helping the rest of the care unit."

@AvaSure #VirtualNurse #VirtualCare #NurseLeaders #RegisteredNurse #AcuteCare #Nurses #Telesitter #Hospitals #DigitalHealth

AvaSure.com

Listen to the podcast here

Lisbeth Votruba, Chief Clinical Officer at AvaSure, reflects on the challenges for nurses and hospitals in these times of nursing shortages, burnout, and expedited retirements. The AvaSure solutions provide virtual nursing, safety monitoring, and expert virtual nursing to monitor critically ill and high-acuity patients. Experienced nurses and those trained as virtual nurses embrace this solution as a way to care for patients while supporting the efficient use of hospital resources for bedside care.

Lisbeth explains, "The first model that I'll talk about is the Telesitter® solution, which supports nurses indirectly. This involves using mobile devices or sometimes fixed cameras with really amazing audio in patient rooms. We are using that to keep patients safe, prevent falls, prevent elopement. This also was used to protect nurses from COVID because patients were ripping off their oxygen masks because they were confused and reminding them to put their masks back on again."

"Prior to this revolution in virtual patient monitoring in the hospital setting, the only thing that hospitals could think to do was assign one-to-one what they called "sitters" to confused or at-risk patients. So 5% of the hospital census would have a staff member, not a nurse, a nursing assistant sitting 24/7, watching them and trying to keep them safe physically. The Telesitter® solution allows one remote, trained staff member to monitor 12 to 16 patients, interacting with them, talking to them, and sometimes needing to use alarms to keep them safe. That frees up that bedside staff to be back out helping the rest of the care unit."

@AvaSure #VirtualNurse #VirtualCare #NurseLeaders #RegisteredNurse #AcuteCare #Nurses #Telesitter #Hospitals #DigitalHealth

AvaSure.com

Download the transcript here

Rayne Guest, the Founder and CEO of ArrowClean, raises the alarm about the lack of effectiveness of traditional disinfectants to eliminate superbugs and other contaminants. Some of the most vulnerable people are in hospitals where patients and staff are exposed to germs, many of which are not treatable. ArrowClean is bringing a hypoallergenic, environmentally safe solution to the disinfectant industry.

Rayne explains, "We have hand sanitizers that take forever to work. Nobody's using them properly. We have people that are not disinfecting properly. They're not letting disinfectants sit long enough on surfaces to kill bugs. Most disinfectants don't kill superbugs because there are different types of pathogens. And a lot of disinfectants also cause harm to human and environmental health. So, it's kind of like we're stacking the cards against ourselves in a lot of ways."

"We have a patented device that creates hundreds of gallons of disinfectant and cleaner in a day. It has that capability. The products that come out of the device are hypoallergenic, and they kill germs really fast. A lot of products and disinfectants are out on the market, and you actually have to keep them wet on the surface for 10 minutes for them to work, for them to kill the germs that they say they kill."

#ArrowClean #Superbugs #Disinfectant #Hospitals

ArrowClean.com

Listen to the podcast here

Rayne Guest, the Founder and CEO of ArrowClean, raises the alarm about the lack of effectiveness of traditional disinfectants to eliminate superbugs and other contaminants. Some of the most vulnerable people are in hospitals where patients and staff are exposed to germs, many of which are not treatable. ArrowClean is bringing a hypoallergenic, environmentally safe solution to the disinfectant industry.

Rayne explains, "We have hand sanitizers that take forever to work. Nobody's using them properly. We have people that are not disinfecting properly. They're not letting disinfectants sit long enough on surfaces to kill bugs. Most disinfectants don't kill superbugs because there are different types of pathogens. And a lot of disinfectants also cause harm to human and environmental health. So, it's kind of like we're stacking the cards against ourselves in a lot of ways."

"We have a patented device that creates hundreds of gallons of disinfectant and cleaner in a day. It has that capability. The products that come out of the device are hypoallergenic, and they kill germs really fast. A lot of products and disinfectants are out on the market, and you actually have to keep them wet on the surface for 10 minutes for them to work, for them to kill the germs that they say they kill."

#ArrowClean #Superbugs #Disinfectant #Hospitals

ArrowClean.com

Download the transcript here

Dr. Mark Sumeray is the Chief Medical Officer of Amolyt Pharma, focusing on rare diseases that affect the endocrine system, the hormonal system that regulates essential body functions. Despite the surgeon's best efforts, the parathyroid glands may be damaged or removed when operating on the thyroid gland creating permanent hypoparathyroidism. As a result, the body does not produce sufficient levels of the parathyroid hormone, which regulates the level of calcium in the blood. Current treatment includes large doses of calcium tablets and vitamin D, which does not address disabling symptoms and long-term complications for the kidney, heart, and brain.

Mark explains, "If you have a deficiency of a hormone, in this case, the parathyroid hormone, then the most obvious thing to do is to replace the missing hormone by giving the hormone or something very similar to the hormone to the patient. So instead of the glands producing the hormone as they should do in the normal situation, in this case, we give something that acts like parathyroid hormone by injection."

"The company has a peptide, which is a type of chemical that is made up of building blocks of amino acids that looks very similar to parathyroid hormone, the missing hormone, but has some important differences to it. It's been specifically synthesized or created by chemists to mimic the action of the natural hormone, and it is given by injection every day to patients. And then, as I mentioned right at the beginning, it's currently in early-stage clinical trials."

@AmolytPharma #Hypoparathyroidism #RareEndocrine #TherapeuticPeptides #Endocrine #RareDisease #Acromegaly #Endocrinology

amolytpharma.com

Listen to the podcast here

Dr. Mark Sumeray is the Chief Medical Officer of Amolyt Pharma, focusing on rare diseases that affect the endocrine system, the hormonal system that regulates essential body functions. Despite the surgeon's best efforts, the parathyroid glands may be damaged or removed when operating on the thyroid gland creating permanent hypoparathyroidism. As a result, the body does not produce sufficient levels of the parathyroid hormone, which regulates the level of calcium in the blood. Current treatment includes large doses of calcium tablets and vitamin D, which does not address disabling symptoms and long-term complications for the kidney, heart, and brain.

Mark explains, "If you have a deficiency of a hormone, in this case, the parathyroid hormone, then the most obvious thing to do is to replace the missing hormone by giving the hormone or something very similar to the hormone to the patient. So instead of the glands producing the hormone as they should do in the normal situation, in this case, we give something that acts like parathyroid hormone by injection."

"The company has a peptide, which is a type of chemical that is made up of building blocks of amino acids that looks very similar to parathyroid hormone, the missing hormone, but has some important differences to it. It's been specifically synthesized or created by chemists to mimic the action of the natural hormone, and it is given by injection every day to patients. And then, as I mentioned right at the beginning, it's currently in early-stage clinical trials."

@AmolytPharma #Hypoparathyroidism #RareEndocrine #TherapeuticPeptides #Endocrine #RareDisease #Acromegaly #Endocrinology

amolytpharma.com

Download the transcript here

Rick Hawkins, CEO and Chairman of Lumos Pharma, is developing an oral compound to treat idiopathic pediatric growth hormone deficiency. Currently, the only treatment for this condition is an injection of recombinant growth hormone. The small molecule drug LUM-201 increases the amplitude of the 23-25 peak releases of growth hormone during the day and night and stays within the normal physiology of the endocrine feedback loop.

Rick explains, "Although we are a drug that we're starting with pediatric growth hormone deficiency, there are actually 11 different diseases of growth hormone deficiency. PGHD happens to be one of the largest ones, which is why we are starting there. In addition to the fact that the burden of care, kids taking lots of injections for that period of time, having an oral alternative is a huge step up in not just compliance and ease of use, but the overall burden of care improves dramatically."

"First of all, this is another one of those examples in the pharmaceutical industry where Big Pharma puts a drug on the shelf, and, once again, it takes maybe one individual or a small group of people to understand that this is the drug that really needs to be taken outside the traditional walls of the pharmaceutical industry. In this case, it was Merck. Merck developed this small molecule as an indication in diseases or the symptoms of aging."

"The drug essentially did what it was supposed to do. However, the FDA essentially said you have no regulatory pathway. These are symptoms of aging and really not a disease. So, they put the drug on the shelf."

@Lumos_Pharma #GrowthDeficiencies #GrowthHormoneDeficiency #GrowthDisorders #RareEndocrineDiseases #OraGrowtHTrials #RareDiseases

Lumos-Pharma.com

Listen to the podcast here

Rick Hawkins, CEO and Chairman of Lumos Pharma, is developing an oral compound to treat idiopathic pediatric growth hormone deficiency. Currently, the only treatment for this condition is an injection of recombinant growth hormone. The small molecule drug LUM-201 increases the amplitude of the 23-25 peak releases of growth hormone during the day and night and stays within the normal physiology of the endocrine feedback loop.

Rick explains, "Although we are a drug that we're starting with pediatric growth hormone deficiency, there are actually 11 different diseases of growth hormone deficiency. PGHD happens to be one of the largest ones, which is why we are starting there. In addition to the fact that the burden of care, kids taking lots of injections for that period of time, having an oral alternative is a huge step up in not just compliance and ease of use, but the overall burden of care improves dramatically."

"First of all, this is another one of those examples in the pharmaceutical industry where Big Pharma puts a drug on the shelf, and, once again, it takes maybe one individual or a small group of people to understand that this is the drug that really needs to be taken outside the traditional walls of the pharmaceutical industry. In this case, it was Merck. Merck developed this small molecule as an indication in diseases or the symptoms of aging."

"The drug essentially did what it was supposed to do. However, the FDA essentially said you have no regulatory pathway. These are symptoms of aging and really not a disease. So, they put the drug on the shelf."

@Lumos_Pharma #GrowthDeficiencies #GrowthHormoneDeficiency #GrowthDisorders #RareEndocrineDiseases #OraGrowtHTrials #RareDiseases

Lumos-Pharma.com

Download the transcript here

Ophir Tanz is the Founder and CEO of Pearl, a company utilizing AI to revolutionize the dental industry. Their FDA-cleared product can detect nine different dental conditions. The diagnostic assistance device analyzes radiography images in real-time to identify pathology, existing restorations, and natural anatomy. Their Second Opinion tool is designed to be used by the practitioner to design a precise course of treatment that the patient understands.

Ophir elaborates, "We think dentistry is particularly ripe for the infusion of AI and particularly what we do, which is a form of AI called computer vision, into the category. So first off, dentists capture more x-rays and radiography than any other form of medicine does on an annual basis. And if you look at the levels of concurrence across different practitioners and how they're detecting pathology, you have a disease like interproximal caries or periapical radiolucency or calculus. These are very, very easy to miss, especially at the early stages. So, if you're able to provide a level of assistance and point out areas of interest chairside in a patient-facing manner, that tends to dramatically increase the quality and precision, and accuracy of the diagnosis."

"Computers are able to identify something like 1,000 shades of gray. I think humans are able to identify something like 30 to 50 shades of gray. So it's just much, much more sensitive. And obviously, given that it is a machine, it is entirely consistent and precise in the kind of output that it reveals. We're not going to magically identify anything that is just fundamentally not visible in a radiograph. It's not magic. We are identifying elements that are visible in the radiograph but with a lot of sensitivity."

@Hello_Pearl #Dentristry #Dentist #AI #ArtificialIntelligence #ComputerVision #DentalCare

hellopearl.com

Listen to the podcast here

Ophir Tanz is the Founder and CEO of Pearl, a company utilizing AI to revolutionize the dental industry. Their FDA-cleared product can detect nine different dental conditions. The diagnostic assistance device analyzes radiography images in real-time to identify pathology, existing restorations, and natural anatomy. Their Second Opinion tool is designed to be used by the practitioner to design a precise course of treatment that the patient understands.

Ophir elaborates, "We think dentistry is particularly ripe for the infusion of AI and particularly what we do, which is a form of AI called computer vision, into the category. So first off, dentists capture more x-rays and radiography than any other form of medicine does on an annual basis. And if you look at the levels of concurrence across different practitioners and how they're detecting pathology, you have a disease like interproximal caries or periapical radiolucency or calculus. These are very, very easy to miss, especially at the early stages. So, if you're able to provide a level of assistance and point out areas of interest chairside in a patient-facing manner, that tends to dramatically increase the quality and precision, and accuracy of the diagnosis."

"Computers are able to identify something like 1,000 shades of gray. I think humans are able to identify something like 30 to 50 shades of gray. So it's just much, much more sensitive. And obviously, given that it is a machine, it is entirely consistent and precise in the kind of output that it reveals. We're not going to magically identify anything that is just fundamentally not visible in a radiograph. It's not magic. We are identifying elements that are visible in the radiograph but with a lot of sensitivity."

@Hello_Pearl #Dentristry #Dentist #AI #ArtificialIntelligence #ComputerVision #DentalCare

hellopearl.com

Download the transcript here